Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enro...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2022-10, Vol.101 (40), p.e30871-e30871 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e30871 |
|---|---|
| container_issue | 40 |
| container_start_page | e30871 |
| container_title | Medicine (Baltimore) |
| container_volume | 101 |
| creator | Sugimoto, Rie Satoh, Takeaki Ueda, Akihiro Senju, Takeshi Tanaka, Yuki Yamashita, Shinsaku Koyanagi, Toshimasa Kurashige, Tomoyuki Higuchi, Nobito Nakamura, Tsukasa Tanaka, Masatake Azuma, Yuuki Ohno, Akari Ooho, Aritsune Ooe, Mari Mutsuki, Taiji Uchimura, Koutarou Kuniyoshi, Masami Tada, Seiya Aratake, Yoshifusa Yoshimoto, Tsuyoshi Yamashita, Naoki Harada, Shigeru Nakamuta, Makoto Motomura, Kenta Kohjima, Motoyuki |
| description | To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enrolled in this study. The treatment lines ranged from second to sixth lines. The treatment effect on HCC differed from that during first-line treatment. The treatment effect was determined using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST. The treatment response was different for each MTA immediately prior to atezolizumab + bevacizumab treatment. Tumors treated with lenvatinib followed by atezolizumab + bevacizumab showed rapid growth for a short period of time followed by shrinkage. However, patients who received ramucirumab, sorafenib, and regorafenib did not show such changes. This was likely because of differences in the mechanism of action of the MTA administered immediately beforehand. The side-effect profile differed from that observed in the IMbrave150 phase 3 study of atezolizumab plus bevacizumab, which showed more adverse events related to hepatic reserve. Patients treated with the combination of atezolizumab and bevacizumab after lenvatinib therapy may experience rapid tumor growth and subsequent shrinkage. |
| doi_str_mv | 10.1097/MD.0000000000030871 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9542563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36221372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4509-6476bc085dbd409c0bd5888c2b2e7f8c7449ce6a49a92956dc0848fce13092e13</originalsourceid><addsrcrecordid>eNpdkdtu1DAQhi0EoqXwBEjIL5DiOM7BXCCtWk5SK27g2ho7k43BiSPb2Wr7Trwj3m4pBV_Yo_H3_zP2EPK6ZOclk-3b68tz9ndVrGvLJ-S0rKumqGUjnj6KT8iLGH8wVlYtF8_JSdVwfohPya9Nwlvv7O06gaaLWyPVuANzn0gBIU04Jzr4QNc5YESTQDukIy6QvEHnVgeBGgjGzn4CugS_zVy085bCkDDQyTs0d1SCsMWEPU0jBlj27-iGTqtL1uQamczauOQKdofU64hhB8n6GRyNae33L8mzAVzEV_fnGfn-8cO3i8_F1ddPXy42V4URNZNFI9pGG9bVve4Fk4bpvu66znDNsR060wohDTYgJEgu66bPrOgGg2XFJM_7GXl_9F1WPWF_aC6AU0uwE4S98mDVvzezHdXW75SsBa-bKhtURwOTHxQDDg_akqnD9NT1pfp_eln15nHZB82fcWVAHIEb7_J3xZ9uvcGgRgSXxju_upW84CzzjLWsyBkhq99Rfazx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Sugimoto, Rie ; Satoh, Takeaki ; Ueda, Akihiro ; Senju, Takeshi ; Tanaka, Yuki ; Yamashita, Shinsaku ; Koyanagi, Toshimasa ; Kurashige, Tomoyuki ; Higuchi, Nobito ; Nakamura, Tsukasa ; Tanaka, Masatake ; Azuma, Yuuki ; Ohno, Akari ; Ooho, Aritsune ; Ooe, Mari ; Mutsuki, Taiji ; Uchimura, Koutarou ; Kuniyoshi, Masami ; Tada, Seiya ; Aratake, Yoshifusa ; Yoshimoto, Tsuyoshi ; Yamashita, Naoki ; Harada, Shigeru ; Nakamuta, Makoto ; Motomura, Kenta ; Kohjima, Motoyuki</creator><creatorcontrib>Sugimoto, Rie ; Satoh, Takeaki ; Ueda, Akihiro ; Senju, Takeshi ; Tanaka, Yuki ; Yamashita, Shinsaku ; Koyanagi, Toshimasa ; Kurashige, Tomoyuki ; Higuchi, Nobito ; Nakamura, Tsukasa ; Tanaka, Masatake ; Azuma, Yuuki ; Ohno, Akari ; Ooho, Aritsune ; Ooe, Mari ; Mutsuki, Taiji ; Uchimura, Koutarou ; Kuniyoshi, Masami ; Tada, Seiya ; Aratake, Yoshifusa ; Yoshimoto, Tsuyoshi ; Yamashita, Naoki ; Harada, Shigeru ; Nakamuta, Makoto ; Motomura, Kenta ; Kohjima, Motoyuki ; Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS)</creatorcontrib><description>To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enrolled in this study. The treatment lines ranged from second to sixth lines. The treatment effect on HCC differed from that during first-line treatment. The treatment effect was determined using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST. The treatment response was different for each MTA immediately prior to atezolizumab + bevacizumab treatment. Tumors treated with lenvatinib followed by atezolizumab + bevacizumab showed rapid growth for a short period of time followed by shrinkage. However, patients who received ramucirumab, sorafenib, and regorafenib did not show such changes. This was likely because of differences in the mechanism of action of the MTA administered immediately beforehand. The side-effect profile differed from that observed in the IMbrave150 phase 3 study of atezolizumab plus bevacizumab, which showed more adverse events related to hepatic reserve. Patients treated with the combination of atezolizumab and bevacizumab after lenvatinib therapy may experience rapid tumor growth and subsequent shrinkage.</description><identifier>ISSN: 1536-5964</identifier><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000030871</identifier><identifier>PMID: 36221372</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - therapeutic use ; Bevacizumab - adverse effects ; Carcinoma, Hepatocellular - pathology ; Humans ; Liver Neoplasms - pathology ; Molecular Targeted Therapy ; Observational Study ; Phenylurea Compounds ; Quinolines ; Sorafenib - therapeutic use</subject><ispartof>Medicine (Baltimore), 2022-10, Vol.101 (40), p.e30871-e30871</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4509-6476bc085dbd409c0bd5888c2b2e7f8c7449ce6a49a92956dc0848fce13092e13</citedby><cites>FETCH-LOGICAL-c4509-6476bc085dbd409c0bd5888c2b2e7f8c7449ce6a49a92956dc0848fce13092e13</cites><orcidid>0000-0003-3906-9307</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542563/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542563/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36221372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sugimoto, Rie</creatorcontrib><creatorcontrib>Satoh, Takeaki</creatorcontrib><creatorcontrib>Ueda, Akihiro</creatorcontrib><creatorcontrib>Senju, Takeshi</creatorcontrib><creatorcontrib>Tanaka, Yuki</creatorcontrib><creatorcontrib>Yamashita, Shinsaku</creatorcontrib><creatorcontrib>Koyanagi, Toshimasa</creatorcontrib><creatorcontrib>Kurashige, Tomoyuki</creatorcontrib><creatorcontrib>Higuchi, Nobito</creatorcontrib><creatorcontrib>Nakamura, Tsukasa</creatorcontrib><creatorcontrib>Tanaka, Masatake</creatorcontrib><creatorcontrib>Azuma, Yuuki</creatorcontrib><creatorcontrib>Ohno, Akari</creatorcontrib><creatorcontrib>Ooho, Aritsune</creatorcontrib><creatorcontrib>Ooe, Mari</creatorcontrib><creatorcontrib>Mutsuki, Taiji</creatorcontrib><creatorcontrib>Uchimura, Koutarou</creatorcontrib><creatorcontrib>Kuniyoshi, Masami</creatorcontrib><creatorcontrib>Tada, Seiya</creatorcontrib><creatorcontrib>Aratake, Yoshifusa</creatorcontrib><creatorcontrib>Yoshimoto, Tsuyoshi</creatorcontrib><creatorcontrib>Yamashita, Naoki</creatorcontrib><creatorcontrib>Harada, Shigeru</creatorcontrib><creatorcontrib>Nakamuta, Makoto</creatorcontrib><creatorcontrib>Motomura, Kenta</creatorcontrib><creatorcontrib>Kohjima, Motoyuki</creatorcontrib><creatorcontrib>Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS)</creatorcontrib><title>Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enrolled in this study. The treatment lines ranged from second to sixth lines. The treatment effect on HCC differed from that during first-line treatment. The treatment effect was determined using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST. The treatment response was different for each MTA immediately prior to atezolizumab + bevacizumab treatment. Tumors treated with lenvatinib followed by atezolizumab + bevacizumab showed rapid growth for a short period of time followed by shrinkage. However, patients who received ramucirumab, sorafenib, and regorafenib did not show such changes. This was likely because of differences in the mechanism of action of the MTA administered immediately beforehand. The side-effect profile differed from that observed in the IMbrave150 phase 3 study of atezolizumab plus bevacizumab, which showed more adverse events related to hepatic reserve. Patients treated with the combination of atezolizumab and bevacizumab after lenvatinib therapy may experience rapid tumor growth and subsequent shrinkage.</description><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bevacizumab - adverse effects</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Humans</subject><subject>Liver Neoplasms - pathology</subject><subject>Molecular Targeted Therapy</subject><subject>Observational Study</subject><subject>Phenylurea Compounds</subject><subject>Quinolines</subject><subject>Sorafenib - therapeutic use</subject><issn>1536-5964</issn><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkdtu1DAQhi0EoqXwBEjIL5DiOM7BXCCtWk5SK27g2ho7k43BiSPb2Wr7Trwj3m4pBV_Yo_H3_zP2EPK6ZOclk-3b68tz9ndVrGvLJ-S0rKumqGUjnj6KT8iLGH8wVlYtF8_JSdVwfohPya9Nwlvv7O06gaaLWyPVuANzn0gBIU04Jzr4QNc5YESTQDukIy6QvEHnVgeBGgjGzn4CugS_zVy085bCkDDQyTs0d1SCsMWEPU0jBlj27-iGTqtL1uQamczauOQKdofU64hhB8n6GRyNae33L8mzAVzEV_fnGfn-8cO3i8_F1ddPXy42V4URNZNFI9pGG9bVve4Fk4bpvu66znDNsR060wohDTYgJEgu66bPrOgGg2XFJM_7GXl_9F1WPWF_aC6AU0uwE4S98mDVvzezHdXW75SsBa-bKhtURwOTHxQDDg_akqnD9NT1pfp_eln15nHZB82fcWVAHIEb7_J3xZ9uvcGgRgSXxju_upW84CzzjLWsyBkhq99Rfazx</recordid><startdate>20221007</startdate><enddate>20221007</enddate><creator>Sugimoto, Rie</creator><creator>Satoh, Takeaki</creator><creator>Ueda, Akihiro</creator><creator>Senju, Takeshi</creator><creator>Tanaka, Yuki</creator><creator>Yamashita, Shinsaku</creator><creator>Koyanagi, Toshimasa</creator><creator>Kurashige, Tomoyuki</creator><creator>Higuchi, Nobito</creator><creator>Nakamura, Tsukasa</creator><creator>Tanaka, Masatake</creator><creator>Azuma, Yuuki</creator><creator>Ohno, Akari</creator><creator>Ooho, Aritsune</creator><creator>Ooe, Mari</creator><creator>Mutsuki, Taiji</creator><creator>Uchimura, Koutarou</creator><creator>Kuniyoshi, Masami</creator><creator>Tada, Seiya</creator><creator>Aratake, Yoshifusa</creator><creator>Yoshimoto, Tsuyoshi</creator><creator>Yamashita, Naoki</creator><creator>Harada, Shigeru</creator><creator>Nakamuta, Makoto</creator><creator>Motomura, Kenta</creator><creator>Kohjima, Motoyuki</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3906-9307</orcidid></search><sort><creationdate>20221007</creationdate><title>Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study</title><author>Sugimoto, Rie ; Satoh, Takeaki ; Ueda, Akihiro ; Senju, Takeshi ; Tanaka, Yuki ; Yamashita, Shinsaku ; Koyanagi, Toshimasa ; Kurashige, Tomoyuki ; Higuchi, Nobito ; Nakamura, Tsukasa ; Tanaka, Masatake ; Azuma, Yuuki ; Ohno, Akari ; Ooho, Aritsune ; Ooe, Mari ; Mutsuki, Taiji ; Uchimura, Koutarou ; Kuniyoshi, Masami ; Tada, Seiya ; Aratake, Yoshifusa ; Yoshimoto, Tsuyoshi ; Yamashita, Naoki ; Harada, Shigeru ; Nakamuta, Makoto ; Motomura, Kenta ; Kohjima, Motoyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4509-6476bc085dbd409c0bd5888c2b2e7f8c7449ce6a49a92956dc0848fce13092e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bevacizumab - adverse effects</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Humans</topic><topic>Liver Neoplasms - pathology</topic><topic>Molecular Targeted Therapy</topic><topic>Observational Study</topic><topic>Phenylurea Compounds</topic><topic>Quinolines</topic><topic>Sorafenib - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sugimoto, Rie</creatorcontrib><creatorcontrib>Satoh, Takeaki</creatorcontrib><creatorcontrib>Ueda, Akihiro</creatorcontrib><creatorcontrib>Senju, Takeshi</creatorcontrib><creatorcontrib>Tanaka, Yuki</creatorcontrib><creatorcontrib>Yamashita, Shinsaku</creatorcontrib><creatorcontrib>Koyanagi, Toshimasa</creatorcontrib><creatorcontrib>Kurashige, Tomoyuki</creatorcontrib><creatorcontrib>Higuchi, Nobito</creatorcontrib><creatorcontrib>Nakamura, Tsukasa</creatorcontrib><creatorcontrib>Tanaka, Masatake</creatorcontrib><creatorcontrib>Azuma, Yuuki</creatorcontrib><creatorcontrib>Ohno, Akari</creatorcontrib><creatorcontrib>Ooho, Aritsune</creatorcontrib><creatorcontrib>Ooe, Mari</creatorcontrib><creatorcontrib>Mutsuki, Taiji</creatorcontrib><creatorcontrib>Uchimura, Koutarou</creatorcontrib><creatorcontrib>Kuniyoshi, Masami</creatorcontrib><creatorcontrib>Tada, Seiya</creatorcontrib><creatorcontrib>Aratake, Yoshifusa</creatorcontrib><creatorcontrib>Yoshimoto, Tsuyoshi</creatorcontrib><creatorcontrib>Yamashita, Naoki</creatorcontrib><creatorcontrib>Harada, Shigeru</creatorcontrib><creatorcontrib>Nakamuta, Makoto</creatorcontrib><creatorcontrib>Motomura, Kenta</creatorcontrib><creatorcontrib>Kohjima, Motoyuki</creatorcontrib><creatorcontrib>Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sugimoto, Rie</au><au>Satoh, Takeaki</au><au>Ueda, Akihiro</au><au>Senju, Takeshi</au><au>Tanaka, Yuki</au><au>Yamashita, Shinsaku</au><au>Koyanagi, Toshimasa</au><au>Kurashige, Tomoyuki</au><au>Higuchi, Nobito</au><au>Nakamura, Tsukasa</au><au>Tanaka, Masatake</au><au>Azuma, Yuuki</au><au>Ohno, Akari</au><au>Ooho, Aritsune</au><au>Ooe, Mari</au><au>Mutsuki, Taiji</au><au>Uchimura, Koutarou</au><au>Kuniyoshi, Masami</au><au>Tada, Seiya</au><au>Aratake, Yoshifusa</au><au>Yoshimoto, Tsuyoshi</au><au>Yamashita, Naoki</au><au>Harada, Shigeru</au><au>Nakamuta, Makoto</au><au>Motomura, Kenta</au><au>Kohjima, Motoyuki</au><aucorp>Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2022-10-07</date><risdate>2022</risdate><volume>101</volume><issue>40</issue><spage>e30871</spage><epage>e30871</epage><pages>e30871-e30871</pages><issn>1536-5964</issn><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated with MTAs were enrolled in this study. The treatment lines ranged from second to sixth lines. The treatment effect on HCC differed from that during first-line treatment. The treatment effect was determined using the Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST. The treatment response was different for each MTA immediately prior to atezolizumab + bevacizumab treatment. Tumors treated with lenvatinib followed by atezolizumab + bevacizumab showed rapid growth for a short period of time followed by shrinkage. However, patients who received ramucirumab, sorafenib, and regorafenib did not show such changes. This was likely because of differences in the mechanism of action of the MTA administered immediately beforehand. The side-effect profile differed from that observed in the IMbrave150 phase 3 study of atezolizumab plus bevacizumab, which showed more adverse events related to hepatic reserve. Patients treated with the combination of atezolizumab and bevacizumab after lenvatinib therapy may experience rapid tumor growth and subsequent shrinkage.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>36221372</pmid><doi>10.1097/MD.0000000000030871</doi><orcidid>https://orcid.org/0000-0003-3906-9307</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1536-5964 |
| ispartof | Medicine (Baltimore), 2022-10, Vol.101 (40), p.e30871-e30871 |
| issn | 1536-5964 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9542563 |
| source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal, Humanized Antineoplastic Agents - therapeutic use Bevacizumab - adverse effects Carcinoma, Hepatocellular - pathology Humans Liver Neoplasms - pathology Molecular Targeted Therapy Observational Study Phenylurea Compounds Quinolines Sorafenib - therapeutic use |
| title | Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T18%3A48%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atezolizumab%20plus%20bevacizumab%20treatment%20for%20unresectable%20hepatocellular%20carcinoma%20progressing%20after%20molecular%20targeted%20therapy:%20A%20multicenter%20prospective%20observational%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Sugimoto,%20Rie&rft.aucorp=Liver%20disease%20Investigators%E2%80%99%20Network%20of%20Kyushu%20University%20&%20Surrounding%20Hospitals%20(LINKS)&rft.date=2022-10-07&rft.volume=101&rft.issue=40&rft.spage=e30871&rft.epage=e30871&rft.pages=e30871-e30871&rft.issn=1536-5964&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000030871&rft_dat=%3Cpubmed_cross%3E36221372%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36221372&rfr_iscdi=true |